Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Prelude Therapeutics Q3 2026 Results: Net Loss of $12.5M, Loss Narrows

Prelude Therapeutics reported a net loss of $36.9 million for the nine months ended September 30, 2026, a significant improvement from the $83.0 million loss in the prior year period, driven by a decrease in R&D expenses and $15.9 million in recognized revenue. The company strengthened its balance sheet through a $90.0 million issuance of common stock and pre-funded warrants, ending the period with $142.4 million in total current assets.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue5.66.5
Net income-12.5-19.7
EPS (diluted, $ a share)$-0.12$-0.26

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-13.1%
Operating margin-252.6%
Source

10-Q filed with the SEC, NASDAQ: PRLD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Prelude Therapeutics Inc: key numbers

Share price
$3.41Close, Nov 16
Market cap
$273M
Shares outstanding
80.07MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Prelude Therapeutics Inc

All →
7:10 AM ET 8-K
Financial Results

Prelude Therapeutics Financial Results

Prelude Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $142.7 million which is expected to fund operations into Q2 2028. The company advanced its clinical pipeline with the initiation of a Phase 1 study for PRT13722 in breast cancer and entered a clinical collaboration with Eli Lilly to evaluate combination therapies.

“The first three quarters of 2026 have been a period of strong execution for Prelude. We rapidly advanced two potential first-in-class programs into clinical development including PRT12396, a mutant-selective JAK2V617F inhibitor with disease-modifying potential in myeloproliferative neoplasms (MPNs) and PRT13722, a selective KAT6A degrader with the potential to improve the safety and efficacy of KAT6 inhibition, a clinically validated approach in HR+ breast cancer.”

Kris Vaddi, Ph.D., Chief Executive Officer of Prelude

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.